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Abstract
Background: Recent evidence from developed and developing countries shows clear clinical and public health 
benefit to starting antiretroviral therapy (ART) earlier. While discussions about when to start ART have often focused on 
the clinical risks and benefits, the main issue is one of fair limit-setting. We applied a human rights framework to assess 
a policy of early treatment initiation according to the following criteria: public-health purpose; likely effectiveness; 
specificity; human rights burdens and benefits; potential for less restrictive approaches; and fair administration.
Discussion: According to our analysis, a policy of earlier ART initiation would better serve both public health and 
human rights objectives. We highlight a number of policy approaches that could be taken to help meet this aim, 
including increased international financial support, alternative models of care, and policies to secure the most 
affordable sources of appropriate antiretroviral drugs.
Summary: Widespread implementation of earlier ART initiation is challenging in resource-limited settings. 
Nevertheless, rationing of essential medicines is a restriction of human rights, and the principle of least restriction 
serves to focus attention on alternative measures such as adapting health service models to increase capacity, 
decreasing costs, and seeking additional international funding. Progressive realisation using well-defined steps will be 
necessary to allow for a phased implementation as part of a framework of short-term targets towards nationwide 
policy adoption, and will require international technical and financial support.
Background
Highly active antiretroviral therapy (ART) has trans-
formed HIV/AIDS from a death sentence into a manage-
able, chronic disease. Today, an adult 20 years of age
diagnosed with HIV/AIDS in the developed world can
expect to live at least 23 years [1,2]. In the developing
world, fewer therapeutic options are available for
patients; nevertheless current treatment approaches are
effective at reducing mortality, with studies demonstrat-
ing similar survival outcomes compared to western coun-
tries, at least in the short term [3].
Among the different strategies for improving long-term
survival for people with HIV/AIDS in resource-limited
settings, the question of when to start ART is gaining
increasing attention. Studies from developed and devel-
oping country settings conclude that early initiation
results in substantial gains in survival and reduced inci-
dence of opportunistic infections, in particular tubercu-
losis (TB). However, a number of concerns have been put
forward against starting treatment earlier, namely
increased costs, potential toxicity of treating more
patients longer, and increased burden on health systems.
One approach to disentangling competing policy goals
in a manner supportive of patient need is through a
human rights analysis [4]. Human rights analysis frame-
works provide a methodology for assessing health policy
from a range of different perspectives, and thus provide a
broader analysis that draws on a range of disciplines, in
contrast to more conventional research methods such as
systematic reviews or cost-effective analyses. Such analy-
ses have been applied to a number of different issues of
importance to public health, such as the prevention of
mother-to-child transmission of HIV [5] and manage-
ment of drug-resistant TB [6]. This paper applies such an
analysis to the question of when to start antiretroviral
treatment.
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When to start antiretroviral treatment
HIV infection progresses to AIDS disease as the virus
replicates in cells of the immune system (CD4 cells),
destroying a patient's immune defence and allowing
opportunistic infections to take hold. ART works by pre-
venting viral replication.
The decision of when to start ART is generally made
according to clinical or immunological criteria. Clinical
decisions are based on the presence of one or more severe
opportunistic infections, categorised by the World Health
Organisation (WHO) as stage III and IV AIDS-defining
illnesses. Developed and developing country guidelines
all recommend starting ART if a patient presents with a
stage III or IV infection, though decisions based on such
clinical criteria alone are generally only used in resource-
limited settings where laboratory capacity is limited.
More commonly, the decision to start ART is based on
immunological criteria, as defined by the level of CD4
cells.
Until recently, the level of CD4 indicating ART differed
between developed and developing countries. European
and US guidelines recommend ART initiation at a CD4
cell threshold of 350 cells/μL (moderate immunodefi-
ciency). A policy of deffered initiation (200 cells/μL) was
originally based on concerns related to the accumulative
risks of toxicity and drug resistance [7]. Such concerns
have diminished in recent years as newer medicines have
become available with fewer toxicities and better potency
(reducing the chance of resistance development). The
availability of these newer medicines, together with stud-
ies that have increased the understanding of the risks of
developing life-threatening illnesses over time if ART is
initiated at a low CD4 count, have shifted the risk-benefit
e q u a t i o n  [ 7 ] .  R e c e n t  e v i d e n c e  f r o m  E u r o p e a n  c o h o r t s
showed that starting ART earlier (at least 350 cells/μL)
results in significant survival gains [8].
Guidelines for developing countries have recently been
revised in line with developed world recommendations.
Treatment guidelines issued by the International AIDS
Society in August 2008 state that "the core principle
underlying these guidelines, namely pathogenesis-
directed therapy with regimens designed to achieve full
virologic suppression with minimal toxicity and maximal
simplicity, is applicable to the developing world" [9], and
the latest WHO antiretroviral treatment guidelines for
resource-limited settings released at the end of 2009 rec-
ommend a move towards earlier initiation at CD4 count
<350 cells/μL [10].
However, these recommendations have for the most
part yet to be translated into country-level policy, and
most national guidelines in developing countries con-
tinue to recommend "deferred" ART initiation at CD4
<200 cells/μL (severe immunodeficiency). The main con-
cern for developing countries is that providing treatment
earlier, for longer, would increase overall drug expendi-
ture costs [11]. In addition, other significant health sys-
tems costs are associated with ART provision to large
numbers of people when there are already too few doc-
tors and hospitals are saturated [12]. Finally, given that
most people present at ART services with an even lower
CD4 count of around 100 cells/μL [13], the issue of early
i n i t i a t i o n  h a s  b e e n  a r g u e d  t o  b e  a  m o o t  p o i n t .  T h e s e
issues have led some to voice concern that earlier initia-
tion "may end up doing more harm than good" by weak-
ening already strained ART programmes [14].
Discussion
A number of frameworks have been developed to assess
the impact of public health policy on human rights. We
chose the Mann-Gostin Framework [4] because it is well
suited to the analysis of policies that involve a restriction
of rights, which can be considered to be the case when
ART is deferred. This framework interrogates policy
according to the following questions: what is the public-
health purpose of the policy? What is the likely effective-
ness of the policy in relation to its purpose? Is the policy
well targeted? What are the human rights burdens and
benefits? Is there a less restrictive policy to achieve the
same objective? Are there fair administrative procedures
in place? These considerations are discussed below and
summarised in Additional File 1, Table S1.
What is the public-health purpose?
When analysing the public health purpose of a given pol-
icy, the objectives of the policy should be assessed inde-
pendently of the methods chosen to reach them. The
three main reasons for establishing a restrictive threshold
for initiating ART are: (i) to treat people who need ART;
(ii) to minimise harms caused by prolonged exposure to
toxicity; and (iii) to ration care.
The primary goal of AR T is to decrease HIV -related
morbidity and mortality. The benefits of starting ART in
terms of reduced mortality and morbidity are clear, and
these are most immediately evident when a patient's
immune system is severely compromised, although a
patient's immunological nadir - how low their CD4 count
is allowed to drop - is predictive of how successfully
future ART will benefit them [15].
A related health concern, which was the principal rea-
son for delaying ART in developed countries, is the risk of
accumulated drug toxicities. The main drugs used in
Africa for first-line ART - stavudine, zidovudine, lamivu-
dine, efavirenz, and nevirapine [16] - all have associated
toxicities, including nausea, diarrhoea, and headache;
more severe adverse effects such as acute hepatitis, anae-
mia, neuropathy, lipodystrophy, hypersensitivity, and
pancreatitis; and life-threatening toxicities such as fulmi-
nant hepatitis and lactic acidosis [17].Ford et al. BMC International Health and Human Rights 2010, 10:6
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However, the overriding purpose of maintaining a more
restrictive threshold for initiation is unstated in policy: it
acts as a form of rationing treatment. Rationing can be
defined as "any implicit or explicit mechanisms that allow
people to go without beneficial services" [18].
What is the likely effectiveness of the policy?
With lower CD4 count comes higher risk of mortality and
morbidity. In untreated patients with a high viral load, the
risks of developing AIDS within 6 months are approxi-
mately 40%, 10%, and 3% for CD4 cell count groups <200,
200-349, and >350 cells/μL, respectively [19]. Similarly,
the long-term prognosis for patients on ART is deter-
mined by immune status at initiation: patients starting
ART at a lower CD4 count have a lower chance of long-
term survival [20].
A recent randomised trial conducted in Haiti compar-
ing patients who started ART early (<350 cells/μL) and
those who were deferred (<200 cells/μL) found a 4-fold
increase in mortality and a 2-fold increase in incident TB
in the deferred group [21]. This reduction in TB inci-
dence also suggests a public health benefit to starting ear-
lier where high coverage can be achieved. These data
reinforce evidence from trials in Africa suggesting a
greater survival benefit of starting therapy earlier [22].
While the focus to date has been on opportunistic
infections that are most frequent at CD4 <200 cells/μL,
recent studies have raised concern about the risk of death
from liver, renal, and heart diseases, as well as from "non-
AIDS" cancers; incidence of these diseases is increased at
lower CD4 counts, with significant differences seen
between those with CD4 <350 cells/μL and those with
CD4 >350 cells/μL [23]. Therefore, if reducing mortality
and morbidity is the main objective, then on the basis of
the latest clinical evidence the 350 cells/μL threshold
should be adopted everywhere. HIV-positive pregnant
women should be provided with ART regardless of CD4
count.
Furthermore, models have indicated a public health
benefit in terms of reduced transmission. A modelling
study from South Africa found a 54% reduction of HIV
transmission when therapy is initiated at CD4 <350 cells/
μL as compared to <200 cells/μL [24]. The potential for
broader access to reduce HIV transmission was suggested
by subsequent studies [25].
Concerns about long-term toxicity and drug resistance
have been lessened in the developed world as more
potent and less toxic medicines became available [26-28].
These concerns are still justified in developing countries,
where older drugs with less favourable side-effect profiles
still form the backbone of therapy, but would be largely
overcome with the wider availability of less-toxic drugs.
Withholding medicines is certainly an effective way of
preventing the development of toxicity and resistance in
the short term, but in the long term everyone will eventu-
ally be eligible. Delaying treatment until the CD4 count
has fallen below 300-350 cells/μL carries greater risks
than does starting treatment earlier, provided that less
toxic drugs are available [7].
Rationing care can be viewed as having two legitimate
aims: getting more benefit from available resources by
giving priority to more cost-effective interventions over
less cost-effective ones targeting the same condition, and
allocating available health resources as fairly as possible.
In the first sense, using a low CD4 count as a means to
ration ART could be counterproductive. Symptomatic
patients place the greatest burden on health systems, as
they require multiple doctor consultations and hospitali-
sation. In the same way that provision of ART led to mas-
sive cost savings in terms of avoided hospitalisations and
opportunistic infections [29], the cost savings made by
delaying ART initiation are at least partly offset by the
cost of treating opportunistic infections among those
who present sick (with low CD4). A cost-effectiveness
simulation from South Africa found that earlier initiation
would be cost-effective over a 5-year period [30]. This
means that a restrictive CD4 threshold for treatment ini-
tiation will also be counterproductive in attempting to
allocate resources fairly; "doing less with more" in this
area also implies depriving others of needed interven-
tions towards which these resources could otherwise
have been channelled.
Moreover, even at the lower cut-off of CD4 <200 cells/
μL, still less than half of those eligible for treatment in the
developing world are receiving ART. It must therefore be
acknowledged that CD4 count is not the only criterion, or
even the main one, by which care is currently being
rationed. Lack of capacity within health systems and poor
proximity to health-care entry points play much greater
roles [31].
Is the policy well targeted?
Deferred treatment initiation prioritises those patients in
greatest clinical need of ART, but still excludes substan-
tial numbers of patients at risk. Given that the latest evi-
dence supports initiating treatment at CD4 <350, a cut-
off below that level is a decision to treat some, but not all,
of the patients who would substantially benefit. There-
fore, a policy of deferred initiation can at best be consid-
ered to be moderately well targeted.
In terms of limiting toxicity, the policy is poorly tar-
geted. Although it limits the overall person-time expo-
sure to ART, not all toxicities are cumulative. As everyone
who is HIV-positive will eventually need to be put on
treatment and so will be exposed, the policy only delays
exposure to toxicity, but does not address the underlying
causes: the fact that toxic drugs are being provided when
less toxic alternatives exist.Ford et al. BMC International Health and Human Rights 2010, 10:6
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A major challenge for ART programmes in resource-
poor settings is pre-ART defaulting: patients diagnosed
as HIV-positive but not yet eligible for treatment fall out
of care because they have little reason to visit the clinic.
One recent study from South Africa reported that almost
three-quarters of patients defaulted pre-ART [32]. While
an argument in favour of a lower CD4 threshold could be
that these individuals would be eligible for ART once
their CD4 count has descended to below 200 cells/μL, the
reality is that many of these patients are not seen again
until they are very sick. Raising the threshold could sup-
port this goal by providing more opportunities to enrol
people into treatment and retain them in care before they
become sick.
What are the human rights benefits and burdens?
The United Nations Commission on Human Rights
explicitly recognised "that access to medication in the
context of pandemics such as HIV/AIDS is one funda-
mental element for achieving progressively the full reali-
sation of the right of everyone to the enjoyment of the
highest attainable standard of physical and mental health"
[33]. This right is subject to both progressive and imme-
diate realisation. Article 2 (1) of the International Cove-
nant on Economic, Social and Cultural Rights (ICESCR)
stipulates the right to the highest attainable standard of
health, including access to medicines, is subject to pro-
gressive realisation and resource availability [34]. At the
same time, General Comment 14 of the UN Committee
on Economic, Social and Cultural Rights (CESCR)
declares that states have an immediate obligation to make
essential medicines available and accessible throughout
their jurisdiction [35]. Antiretroviral drugs are defined as
essential medicines [36].
Rationing of ART brings into consideration a number
of human rights principles that are articulated by interna-
tional and regional human rights instruments. The most
relevant concerns covered by these instruments include
the right to life [34,36-38], access to health care [34,36-
38], access to medicines [33,34,37], non-discrimination
[34], protection of the most vulnerable [34], and restric-
tion of rights [37,39,40].
A number of benefits and burdens are associated with
the policy of using a restrictive CD4 count to determine
ART eligibility. The main issues are outlined below.
Benefits
As a general point, from a human rights perspective,
rationing of ART could bring a benefit if it led to broader
access, and thus to greater overall implementation of the
rights to life, access to health care, and access to medi-
cine. This, however, would only be the case if limiting
indications enabled health systems to provide access
more extensively to persons who would otherwise be
deprived of it. For example, this could apply if rationing
was required to make ART available to everyone who met
a lower CD4 threshold, even in rural areas, rather than to
all who presented with the higher threshold, but exclu-
sively at urban centres. Moreover, such a benefit could
only ever be said to exist in circumstances where full
access for all was not feasible. More specifically, one of
the most important aspects of employing medical crite-
ria, as opposed to other forms of rationing such as occu-
pation or social worth [41], is that it meets the criteria of
non-discrimination [42]: everyone meeting the criteria is
given a chance to access treatment via the consistent
application of the same criteria in an objective and trans-
parent manner.
There is, however, a concern regarding the fact that eli-
gibility based on laboratory investigations requires access
to those investigations. While clinical criteria would
determine that a certain proportion of patients should
start treatment, those who would be eligible on immuno-
logical but not clinical grounds would be denied care.
They are in any case likely to be among the most vulnera-
ble, and in some cases this difference in treatment will
even amount to a form of inequity in settings where CD4
is poorly available [41]. However, this applies equally to
any CD4-based initiation strategy, whether early or
deferred. Certainly, CD4 counts provide a more objective
threshold than clinical criteria.
Burdens
The main human rights burden of limiting ART is that it
denies treatment to people who, in other (wealthier) parts
of the world, would be considered eligible. If access to
ART is subject to immediate realisation, and the latest
evidence suggests that ART should be provided earlier,
then from a human rights perspective every effort should
b e  m a d e  t o  e n s u r e  t h i s  h a p p e n s  a n d  h a p p e n s  f o r  a l l .
Higher CD4 count at treatment initiation gives a greater
chance of escaping symptomatic disease. Crudely put, the
current policy is one that lets people progress from hav-
ing a 10% chance of developing AIDS illness within 6
months to a 40% chance. This is in clear conflict with the
human right to the highest attainable standard of health
[34].
Finally, the issue of stigma is important. The common
symptoms of AIDS-defining illnesses are well-known
within communities, and allowing people with HIV to
develop symptoms may increase their risks of being stig-
matised [43]. This represents a violation of the right to
non-discrimination [34]. Stigma can also act as a barrier
to uptake of HIV services [44] and as such goes against
the right to access to health care.
Is there a less restrictive policy to achieve objective?
Human rights doctrine recognises the need to limit cer-
tain human rights, usually in times of public health emer-
gency when certain individual rights are temporarilyFord et al. BMC International Health and Human Rights 2010, 10:6
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restricted over concern for the common good. The most
commonly cited example of such a trade off is the isola-
tion of individuals to prevent the spread of infectious dis-
eases. A core principle of such restrictions is that they are
legitimate, non-arbitrary, and necessary. The Siracusa
Principles on the Limitation and Derogation of Provi-
sions in the International Covenant on Civil and Political
Rights state that: "Public health may be invoked as a
ground for limiting certain rights in order to allow a state
to take measures dealing with a serious threat to the
health of the population or individual members of the
population. These measures must be specifically aimed at
preventing disease or injury or providing care for the sick
and injured" [45].
Human rights considerations require that where differ-
ent policy options may be pursued to reach the same
objective, the less-restrictive policy should be applied. In
terms of meeting the stated public health objectives of
reducing mortality and morbidity, increasing the thresh-
old to 350 cells/μL would be less restrictive. In regards to
limiting exposure to toxic drugs, a number of medicines
are available today with a better toxicity profiles than
those most widely used in the developing world. One of
the most severe side effects, lactic acidosis, can be largely
avoided by replacing one drug (stavudine) with less toxic
alternatives (tenofovir or abacavir). However, these drugs
are currently more expensive and widespread adoption
will likely require a reduction in price [46]; of note, mech-
anisms which have been successful in influencing drug
prices and encouraging generic competition also include
the use of public health safeguards [47-49]]. Thailand and
Brazil, for example, have both issued compulsory licenses
to enable them to purchase generic versions of tenofovir,
which is more affordable than the patented version [48].
The Indian patent office recently rejected the patent on
tenofovir, allowing generic production [49]. The global
price for tenofovir has fallen commensurate with an
increase in generic production [28].
Any policy to ration essential care is by definition
restrictive, and such restrictions are a feature of health
care across the world. However, policies that restrict
essential health services on the basis of limited resources
have been challenged elsewhere. In the UK for example, a
high court decision regarding the rationing of leukaemia
chemotherapy ruled that the health authorities' power to
refuse treatment on grounds of resource shortage were
severely limited, and that the authorities had to prove
that the money saved by rationing was being better
placed elsewhere [50]. Although made in a developed
country, this ruling makes the general point that if ration-
ing is being employed, it is incumbent on the state to
demonstrate that resources saved in one area are meeting
important priorities elsewhere.
Recent cuts in the HIV/AIDS budgets in some develop-
ing countries suggest that this is not the case [51]. In the
case of HIV/AIDS treatment, a substantial portion of
funding comes from the international community, nota-
bly developed countries who do not themselves apply
such limiting criteria. Although most human rights docu-
ments address the duties of states towards their own citi-
zens only, this is a case where, arguably, this limitation
does not fully apply. As pointed out by UN Committee on
Economic, Social and Cultural Rights "...given that some
diseases are easily transmissible beyond the frontiers of a
State, the international community has a collective
responsibility to address this problem. The economically
developed States parties have a special responsibility and
interest to assist the poorer developing States in this
regard" [29]. HIV/AIDS clearly falls into this category. It
is therefore also incumbent on donor countries to justify
why they do not support a policy of earlier initiation.
Part of the justification for rationing is based on the fact
that current ART sites are overburdened. Much could be
done to increase capacity by increasing efficiency, which
would be a less restrictive alternative to rationing. Vari-
ous national and international guidelines recommend
ways of doing this. One such measure is the task-shifting
of clinical responsibilities from doctors to nurses and the
deployment of community health workers to overcome
severe human resource shortages [52]. There are also
emerging decentralised models of how to manage "stable"
patients out-of-facility [53]. Such approaches provide
alternative ways of improving cost savings and increasing
access despite bottlenecks due to doctor shortages, and
are consistent with health-systems approaches support-
ing the right to the highest attainable standard of health
[54].
Finally, international financing already supports a sub-
stantial part of the AIDS response [55]. This is not mere
charity on the part of wealthier countries, but is consis-
tent with their obligation under international human
rights law to provide resources to support the realisation
of "core and other obligations," which includes access to
ART [56].
Are fair administrative procedures in place?
A human rights-based approach to HIV care means
ensuring transparency and accountability for how poli-
cies and programmes are carried out. This relates to a
state's duty to promote human rights by providing rights
holders with sufficient information to realise their rights
[57]. The requirement for fair administrative procedures
means that the policy - in this instance, to ration ART by
CD4 count, or relying on clinical criteria where CD4
measures are not possible - is based on adequate assess-
ment of all relevant evidence and that safeguards are inFord et al. BMC International Health and Human Rights 2010, 10:6
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place to provide opportunities for appeal and review, and
that all parties understand the reasons behind the deci-
sions taken [58]. Most national guidelines in developing
countries do not adequately reflect the latest evidence
regarding the clinical and public health benefits of initiat-
ing therapy at the higher threshold of CD4 <350 cells/μL.
Moreover, it is unlikely that the decision to ration treat-
ment in this way is properly understood by health provid-
ers and recipients (patients). In particular, the high rate of
defaulting among HIV-positive patients who are not yet
eligible for ART suggests that many do not understand
the need to remain in care until eligibility requirements
are met.
Overall, is the policy the optimal approach to the problem?
From this analysis, the policy is suboptimal in terms of
addressing the public health and human rights issues in
terms of reducing mortality and morbidity, limiting toxic-
ity, supporting public health goals, and rationing.
Alternative frameworks for assessing rationing decisions
It has been argued that "No single analytical framework -
whether grounded in economics, social sciences, ethics
or human rights - can determine to everyone's satisfac-
tion who should benefit from services first, second or
last."[57]
Human rights principles of restriction of rights have
most often been looked at from a perspective of restric-
tion of movement [5] but could also be employed to anal-
yse rationing decisions. Ethics and human rights are
interconnected; both are based on the core principles of
the respectful and dignified treatment of persons [58].
Since the inclusion of a right to health within the Human
Rights framework, both also recognise a right to health
care. Currently, the most influential ethical defence of
such a right is based on the fact that health is a prerequi-
site if we are to have access to the life choices which
should be open to everyone [59-61]. Although a full dis-
cussion is beyond the scope of this paper, this is arguably
particularly relevant to access to ART, as without it
patients are vulnerable to stigma, disability, and death All
three effectively close options that these patients should
have, and which treatment can reopen. Inasmuch as
stigma compounds other sources of vulnerability, this
may even constitute a reason to give a degree of priority
to ART in health care resource allocation [62].
Discussions of ethical aspects of rationing have focused
on individual-level access and decisions, as well as insti-
tutional or national priorities in resource allocation [63].
These discussions have however tended to focus less on
public-health interventions than on clinical or other
health policy decisions. T wo recent examples from the
US - oseltamivir and influenza vaccine - have looked at
rationing from a public health perspective. In the case of
oseltamivir (an antiviral drug for the treatment of influ-
enza) it was argued that while, in general, doctors should
defer to patients' requests for a treatment that provided a
modicum of benefit, where the drug is limited in quantity,
physicians should be guided by principles of public-
health ethics (maximising the health of the population
while minimising infringements on individual liberty)
[64]. Public discussions about rationing were limited for
fear of evoking panic, allowing "invisible" rationing deci-
sions to be made [65]. Similar considerations were
brought to bear in the case of influenza vaccine, where
rationing was accepted by health professionals and doc-
tors as a necessary way to manage limited resources [66].
However, broader decisions about resource allocation
were based on prioritising key personnel that by defini-
tion excluded those who were unemployed or in "nones-
sential" jobs. While this can ensure greater protection for
a broader public, it can also exclude the most disenfran-
chised populations, thereby promoting social injustice
[67].
Both of these issues - lack of discussion and the choice
of prioritisation criteria - are ethically problematic. The
main point emphasised in both these examples is the
need for public discourse to ensure transparency in deci-
sion-making. This has become an increasing focus of eth-
ical discussions as attempts to identify generally
justifiable criteria for allocation failed, and has led to the
development of philosophical frameworks for procedural
justice in resource allocation [68]. This need is broadly
recognised: when the recent trial data showed the bene-
fits of earlier initiation, patient groups in South Africa
immediately demanded a change in guidelines [69]. Nev-
ertheless, the involvement of people with HIV/AIDS in
such decisions is at best limited to public advocacy; they
are rarely invited to the policy table. Thus, a need exists
to explicitly frame and debate the main issues at stake by
engaging key stakeholders from all sides - government,
providers, civil society, and patients. Such debate should
not be limited to narrow cost concerns but should con-
sider broader principles that apply to rationing policies
such as justice, reciprocity, consistency, explicitness, and
revisability [70]. Public debate is also needed to gain
political support for moving towards a policy that would
effectively result in a drop in ART coverage as the num-
ber of people in need of treatment will increase.
Summary
The latest evidence on risks to health for people with HIV
at CD4 counts above 200 cells/μL, together with the avail-
ably of newer, less toxic drugs, support the raising of the
threshold of ART initiation from public health, ethical,
and human rights perspectives. Guidelines for developed
countries have adopted a higher cut-off for ART eligibil-
ity, and international guidelines for developing countriesFord et al. BMC International Health and Human Rights 2010, 10:6
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have recently been amended to support earlier initiation.
However, most national-level guidelines continue to rec-
ommend deferring treatment to 200 cells/μL, a policy
that, in human rights terms, falls into the category of
"impermissible under-inclusiveness" [4].
This paper aims to show that a human rights analysis
can contribute to more considered deliberation regarding
the way forward, from which concrete policy options can
emerge (Additional File 2, Table S2). The framework used
here serves to clarify a number of important issues. The
first step was to clarify the public health purpose. Clearly
no medical reason exists for why deferred ART initiation
should be preferred. Rather, the principal purpose of
starting treatment later is to ration care. Rationing of
essential medicines is a restriction of human rights, and
the principle of least restriction serves to focus attention
on alternative measures such as implementing policies
that would increase capacity and decrease costs of care,
and seeking additional funding to support ART expan-
sion. Finally, where resources remain insufficient to pro-
vide early treatment for all, different views exist among
governments, academia, civil society, and donors, and the
principal of fair administration highlights the need to dis-
cuss these issues in a transparent manner involving all
relevant stakeholders.
More data are needed on the cost-effectiveness of start-
ing ART earlier, including not only the costs associated
with treating opportunistic infections but also the costs
of delaying ART [30]. Such evidence could be gained
through the gradual adoption of an earlier threshold for
initiation in pilot sites. This would also allow for impor-
tant lessons to be learnt in terms of training staff, educat-
ing patients, and scaling up services. Such cost
effectiveness data will be critical given that a shift
towards earlier initiation will require both affected-coun-
try governments and the international community to pro-
vide additional funding to support expansion of care,
even if long-term savings can be anticipated. Finally,
implementation of these new recommendations is chal-
lenging. Progressive realisation using well-defined steps
will be necessary to allow for a phased implementation as
part of a framework of short-term targets towards nation-
wide policy adoption.
In conclusion, we believe that instead of continuing a
policy of rationing ART based on medical criteria that
have been abandoned elsewhere, governments should
revise the initiation threshold in line with international
recommendations, adopt a treatment policy that includes
the use of less-toxic drugs, and implement cost-effective
policies such as task-shifting and sourcing of more
affordable medicines on the international market. Such
measures require clear technical and financial support
from donor governments that are currently applying a
d o u b l e  s t a n d a r d  b y  s u p p o r t i n g  A R T  c a r e  w i t h  r e s t r i c -
tions to access that they themselves would not accept.
Indeed, it is their duty under international law to provide
such assistance.
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